---
document_datetime: 2025-11-23 08:06:43
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ibandronic-acid-teva.html
document_name: ibandronic-acid-teva.html
version: success
processing_time: 0.1247316
conversion_datetime: 2025-12-24 21:56:28.029124
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ibandronic Acid Teva

[RSS](/en/individual-human-medicine.xml/66883)

##### Authorised

This medicine is authorised for use in the European Union

ibandronic acid

Medicine

Human

Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Ibandronic Acid Teva](#news-on)
- [More information on Ibandronic Acid Teva](#more-information-on-ibandronic-acid-teva-1467)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Ibandronic Acid Teva. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ibandronic Acid Teva.

Expand section

Collapse section

## What is Ibandronic Acid Teva?

Ibandronic Acid Teva is a medicine that contains the active substance ibandronic acid. It is available as tablets (50 and 150 mg).

Ibandronic Acid Teva is a 'generic medicine'. This means that Ibandronic Acid Teva is similar to a 'reference medicine' already authorised in the European Union (EU). The reference medicines for Ibandronic Acid Teva are Bondronat and Bonviva.

## What is Ibandronic Acid Teva used for?

Ibandronic Acid Teva 50 mg is used to prevent 'skeletal events' (fractures [broken bones] or bone complications requiring treatment) in patients with breast cancer and bone metastases (when the cancer has spread to the bone).

Ibandronic Acid Teva 150 mg is used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and are at risk of developing bone fractures. Its effect in reducing the risk of spine fractures has been shown in studies, but its effect on the risk of fractures of the neck of the femur (the top of the thighbone) has not been established.

The medicine can only be obtained with a prescription.

## How is Ibandronic Acid Teva used?

For the prevention of skeletal events, one 50?mg tablet is taken once a day. The tablets must always be taken after the patient has fasted overnight for at least six hours and at least 30 minutes before the first food or drink of the day.

For treating osteoporosis, one 150?mg tablet is taken once a month. The tablet must always be taken after an overnight fast, one hour before any food or drink except for water. Patients should also take vitamin D and calcium supplements if they do not get enough from their diet.

Ibandronic Acid Teva must be taken with a full glass of plain water (but not mineral water) while standing or sitting up, and the tablets should not be chewed, sucked or crushed. The patient must also not lie down for one hour after taking the tablets.

## How does Ibandronic Acid Teva work?

The active substance in Ibandronic Acid Teva, ibandronic acid, is a bisphosphonate. It stops the action of osteoclasts, the cells in the body that are involved in breaking down the bone tissue. This leads to less bone loss. The reduction of bone loss helps to make bones less likely to break, which is useful in preventing fractures in cancer patients with bone metastases and in women with osteoporosis.

## How has Ibandronic Acid Teva been studied?

Because Ibandronic Acid Teva is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicines. Medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefit and risk of Ibandronic Acid Teva?

Because Ibandronic Acid Teva is a generic medicine and is bioequivalent to the reference medicines, its benefits and risks are taken as being the same as the reference medicines's.

## Why has Ibandronic Acid Teva been approved?

The CHMP concluded that, in accordance with EU requirements, Ibandronic Acid Teva has been shown to have comparable quality and to be bioequivalent to Bondronat and Bonviva. Therefore, the CHMP's view was that, as for Bondronat and Bonviva, the benefit outweighs the identified risk. The Committee recommended that Ibandronic Acid Teva be given marketing authorisation.

## Other information about Ibandronic Acid Teva

The European Commission granted a marketing authorisation valid throughout the EU for Ibandronic Acid Teva on 17 September 2010.

For more information about treatment with Ibandronic Acid Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Ibandronic Acid Teva : EPAR - Summary for the public

English (EN) (79.66 KB - PDF)

**First published:** 13/10/2010

**Last updated:** 30/09/2015

[View](/en/documents/overview/ibandronic-acid-teva-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-106)

български (BG) (109.32 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

30/09/2015

[View](/bg/documents/overview/ibandronic-acid-teva-epar-summary-public_bg.pdf)

español (ES) (86.22 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

30/09/2015

[View](/es/documents/overview/ibandronic-acid-teva-epar-summary-public_es.pdf)

čeština (CS) (106.36 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

30/09/2015

[View](/cs/documents/overview/ibandronic-acid-teva-epar-summary-public_cs.pdf)

dansk (DA) (84.75 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

30/09/2015

[View](/da/documents/overview/ibandronic-acid-teva-epar-summary-public_da.pdf)

Deutsch (DE) (87.2 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

30/09/2015

[View](/de/documents/overview/ibandronic-acid-teva-epar-summary-public_de.pdf)

eesti keel (ET) (84.49 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

30/09/2015

[View](/et/documents/overview/ibandronic-acid-teva-epar-summary-public_et.pdf)

ελληνικά (EL) (110.69 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

30/09/2015

[View](/el/documents/overview/ibandronic-acid-teva-epar-summary-public_el.pdf)

français (FR) (86.95 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

30/09/2015

[View](/fr/documents/overview/ibandronic-acid-teva-epar-summary-public_fr.pdf)

hrvatski (HR) (91 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

30/09/2015

[View](/hr/documents/overview/ibandronic-acid-teva-epar-summary-public_hr.pdf)

italiano (IT) (85.12 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

30/09/2015

[View](/it/documents/overview/ibandronic-acid-teva-epar-summary-public_it.pdf)

latviešu valoda (LV) (101.45 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

30/09/2015

[View](/lv/documents/overview/ibandronic-acid-teva-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (101.94 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

30/09/2015

[View](/lt/documents/overview/ibandronic-acid-teva-epar-summary-public_lt.pdf)

magyar (HU) (100.51 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

30/09/2015

[View](/hu/documents/overview/ibandronic-acid-teva-epar-summary-public_hu.pdf)

Malti (MT) (104.32 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

30/09/2015

[View](/mt/documents/overview/ibandronic-acid-teva-epar-summary-public_mt.pdf)

Nederlands (NL) (86.79 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

30/09/2015

[View](/nl/documents/overview/ibandronic-acid-teva-epar-summary-public_nl.pdf)

polski (PL) (105.64 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

30/09/2015

[View](/pl/documents/overview/ibandronic-acid-teva-epar-summary-public_pl.pdf)

português (PT) (86.66 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

30/09/2015

[View](/pt/documents/overview/ibandronic-acid-teva-epar-summary-public_pt.pdf)

română (RO) (101.21 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

30/09/2015

[View](/ro/documents/overview/ibandronic-acid-teva-epar-summary-public_ro.pdf)

slovenčina (SK) (104 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

30/09/2015

[View](/sk/documents/overview/ibandronic-acid-teva-epar-summary-public_sk.pdf)

slovenščina (SL) (90.82 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

30/09/2015

[View](/sl/documents/overview/ibandronic-acid-teva-epar-summary-public_sl.pdf)

Suomi (FI) (84.79 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

30/09/2015

[View](/fi/documents/overview/ibandronic-acid-teva-epar-summary-public_fi.pdf)

svenska (SV) (84.99 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

30/09/2015

[View](/sv/documents/overview/ibandronic-acid-teva-epar-summary-public_sv.pdf)

## Product information

Ibandronic Acid Teva : EPAR - Product Information

English (EN) (406.03 KB - PDF)

**First published:** 13/10/2010

**Last updated:** 28/08/2024

[View](/en/documents/product-information/ibandronic-acid-teva-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-719)

български (BG) (546.39 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

28/08/2024

[View](/bg/documents/product-information/ibandronic-acid-teva-epar-product-information_bg.pdf)

español (ES) (459.47 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

28/08/2024

[View](/es/documents/product-information/ibandronic-acid-teva-epar-product-information_es.pdf)

čeština (CS) (527.01 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

28/08/2024

[View](/cs/documents/product-information/ibandronic-acid-teva-epar-product-information_cs.pdf)

dansk (DA) (422.66 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

28/08/2024

[View](/da/documents/product-information/ibandronic-acid-teva-epar-product-information_da.pdf)

Deutsch (DE) (446.85 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

28/08/2024

[View](/de/documents/product-information/ibandronic-acid-teva-epar-product-information_de.pdf)

eesti keel (ET) (404.67 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

28/08/2024

[View](/et/documents/product-information/ibandronic-acid-teva-epar-product-information_et.pdf)

ελληνικά (EL) (561 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

28/08/2024

[View](/el/documents/product-information/ibandronic-acid-teva-epar-product-information_el.pdf)

français (FR) (458 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

28/08/2024

[View](/fr/documents/product-information/ibandronic-acid-teva-epar-product-information_fr.pdf)

hrvatski (HR) (512.79 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

28/08/2024

[View](/hr/documents/product-information/ibandronic-acid-teva-epar-product-information_hr.pdf)

íslenska (IS) (410.75 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

28/08/2024

[View](/is/documents/product-information/ibandronic-acid-teva-epar-product-information_is.pdf)

italiano (IT) (437.77 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

28/08/2024

[View](/it/documents/product-information/ibandronic-acid-teva-epar-product-information_it.pdf)

latviešu valoda (LV) (514.51 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

28/08/2024

[View](/lv/documents/product-information/ibandronic-acid-teva-epar-product-information_lv.pdf)

lietuvių kalba (LT) (539.01 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

28/08/2024

[View](/lt/documents/product-information/ibandronic-acid-teva-epar-product-information_lt.pdf)

magyar (HU) (499.81 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

28/08/2024

[View](/hu/documents/product-information/ibandronic-acid-teva-epar-product-information_hu.pdf)

Malti (MT) (567.53 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

28/08/2024

[View](/mt/documents/product-information/ibandronic-acid-teva-epar-product-information_mt.pdf)

Nederlands (NL) (434.29 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

28/08/2024

[View](/nl/documents/product-information/ibandronic-acid-teva-epar-product-information_nl.pdf)

norsk (NO) (414.92 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

28/08/2024

[View](/no/documents/product-information/ibandronic-acid-teva-epar-product-information_no.pdf)

polski (PL) (552.64 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

28/08/2024

[View](/pl/documents/product-information/ibandronic-acid-teva-epar-product-information_pl.pdf)

português (PT) (449.66 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

28/08/2024

[View](/pt/documents/product-information/ibandronic-acid-teva-epar-product-information_pt.pdf)

română (RO) (549.02 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

28/08/2024

[View](/ro/documents/product-information/ibandronic-acid-teva-epar-product-information_ro.pdf)

slovenčina (SK) (545.73 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

28/08/2024

[View](/sk/documents/product-information/ibandronic-acid-teva-epar-product-information_sk.pdf)

slovenščina (SL) (492.29 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

28/08/2024

[View](/sl/documents/product-information/ibandronic-acid-teva-epar-product-information_sl.pdf)

Suomi (FI) (428.91 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

28/08/2024

[View](/fi/documents/product-information/ibandronic-acid-teva-epar-product-information_fi.pdf)

svenska (SV) (417.43 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

28/08/2024

[View](/sv/documents/product-information/ibandronic-acid-teva-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0022 16/08/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ibandronic Acid Teva : EPAR - All Authorised presentations

English (EN) (25.38 KB - PDF)

**First published:** 13/10/2010

**Last updated:** 13/10/2010

[View](/en/documents/all-authorised-presentations/ibandronic-acid-teva-epar-all-authorised-presentations_en.pdf)

[Other languages (21)](#file-language-dropdown-25)

български (BG) (92.54 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

13/10/2010

[View](/bg/documents/all-authorised-presentations/ibandronic-acid-teva-epar-all-authorised-presentations_bg.pdf)

español (ES) (26.66 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

13/10/2010

[View](/es/documents/all-authorised-presentations/ibandronic-acid-teva-epar-all-authorised-presentations_es.pdf)

čeština (CS) (54.62 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

13/10/2010

[View](/cs/documents/all-authorised-presentations/ibandronic-acid-teva-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (25.57 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

13/10/2010

[View](/da/documents/all-authorised-presentations/ibandronic-acid-teva-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (22.68 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

13/10/2010

[View](/de/documents/all-authorised-presentations/ibandronic-acid-teva-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (25.89 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

13/10/2010

[View](/et/documents/all-authorised-presentations/ibandronic-acid-teva-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (86.21 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

13/10/2010

[View](/el/documents/all-authorised-presentations/ibandronic-acid-teva-epar-all-authorised-presentations_el.pdf)

français (FR) (26.04 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

13/10/2010

[View](/fr/documents/all-authorised-presentations/ibandronic-acid-teva-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (25.52 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

13/10/2010

[View](/it/documents/all-authorised-presentations/ibandronic-acid-teva-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (91.45 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

13/10/2010

[View](/lv/documents/all-authorised-presentations/ibandronic-acid-teva-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (89.65 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

13/10/2010

[View](/lt/documents/all-authorised-presentations/ibandronic-acid-teva-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (92.31 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

13/10/2010

[View](/hu/documents/all-authorised-presentations/ibandronic-acid-teva-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (90.19 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

13/10/2010

[View](/mt/documents/all-authorised-presentations/ibandronic-acid-teva-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (25.51 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

13/10/2010

[View](/nl/documents/all-authorised-presentations/ibandronic-acid-teva-epar-all-authorised-presentations_nl.pdf)

polski (PL) (55.47 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

13/10/2010

[View](/pl/documents/all-authorised-presentations/ibandronic-acid-teva-epar-all-authorised-presentations_pl.pdf)

português (PT) (26.68 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

13/10/2010

[View](/pt/documents/all-authorised-presentations/ibandronic-acid-teva-epar-all-authorised-presentations_pt.pdf)

română (RO) (88.05 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

13/10/2010

[View](/ro/documents/all-authorised-presentations/ibandronic-acid-teva-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (55.2 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

13/10/2010

[View](/sk/documents/all-authorised-presentations/ibandronic-acid-teva-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (24.92 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

13/10/2010

[View](/sl/documents/all-authorised-presentations/ibandronic-acid-teva-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (24.75 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

13/10/2010

[View](/fi/documents/all-authorised-presentations/ibandronic-acid-teva-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (24.73 KB - PDF)

**First published:**

13/10/2010

**Last updated:**

13/10/2010

[View](/sv/documents/all-authorised-presentations/ibandronic-acid-teva-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ibandronic Acid Teva Active substance ibandronic acid International non-proprietary name (INN) or common name ibandronic acid Therapeutic area (MeSH)

- Breast Neoplasms
- Neoplasm Metastasis
- Fractures, Bone
- Osteoporosis, Postmenopausal

Anatomical therapeutic chemical (ATC) code M05BA06

### Pharmacotherapeutic group

Drugs for treatment of bone diseases

### Therapeutic indication

**Ibandronic acid 50mg**

Ibandronic Acid Teva is indicated for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.

**Ibandronic acid 150mg**

Treatment of osteoporosis in postmenopausal women at increased risk of fracture. A reduction in the risk of vertebral fractures has been demonstrated, efficacy on femoral neck fractures has not been established.

## Authorisation details

EMA product number EMEA/H/C/001195

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Teva Pharma B.V.

Computerweg 10

Opinion adopted 24/06/2010 Marketing authorisation issued 17/09/2010 Revision 13

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ibandronic Acid Teva : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (127.72 KB - PDF)

**First published:** 13/09/2011

**Last updated:** 28/08/2024

[View](/en/documents/procedural-steps-after/ibandronic-acid-teva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Ibandronic Acid Teva-H-C-1195-A20-0001 : EPAR - Assessment Report - Article-20

Adopted

Reference Number: EMA/543436/2011

English (EN) (124.65 KB - PDF)

**First published:** 13/09/2011

**Last updated:** 13/09/2011

[View](/en/documents/variation-report/ibandronic-acid-teva-h-c-1195-a20-0001-epar-assessment-report-article-20_en.pdf)

## Initial marketing authorisation documents

Ibandronic Acid Teva : EPAR - Public assessment report

English (EN) (251.28 KB - PDF)

**First published:** 13/10/2010

**Last updated:** 13/10/2010

[View](/en/documents/assessment-report/ibandronic-acid-teva-epar-public-assessment-report_en.pdf)

CHMP positive summary of opinion for Ibandronic Acid Teva

Adopted

Reference Number: EMA/CHMP/390850/2010

English (EN) (48.52 KB - PDF)

**First published:** 25/06/2010

**Last updated:** 25/06/2010

[View](/en/documents/smop-initial/chmp-positive-summary-opinion-ibandronic-acid-teva_en.pdf)

#### News on Ibandronic Acid Teva

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 March 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-march-2012) 16/03/2012

#### More information on Ibandronic Acid Teva

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-44)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 28/08/2024

## Share this page

[Back to top](#main-content)